Impostors out! - 30 mins
Articles from: The Lancet Haematology
Mashup Score:26
The Lancet HaematologySusan Kahn—a long-term look at thrombosis - 19 hours
Mashup Score:26
Lifelong Montrealer Susan Kahn has dedicated her career to helping people who experience thrombosis, from those diagnosed with cancers to young women that are...
-
NEW: Our Profile on @SusanRKahn1, Director of the Centre of Excellence in Thrombosis and Anticoagulation Care (Montreal, Canada), describes her career dedicated to helping people with #thrombosis. https://t.co/Q3xkcTDHkS - view on twitter
More coverage:
#thrombosis
Mashup Score:11
The Lancet HaematologySickle cell disease care in Lebanon: resource-constrained and humanitarian crisis adaptations - 1 day
Mashup Score:11
Lebanon is a small country in the Eastern Mediterranean. There are 4 million Lebanese residing in the country, and according to the WHO Annual...
-
NEW: In thier Global Haematology piece, @YazbekSoha and colleagues describe how the @AUBMC_Official Sickle Cell Programme provides patients with #SickleCell disease residing in Lebanon an equal chance to receive a disease-specific, patient-centred care. https://t.co/7k6vrF7DGt - view on twitter
More coverage:
#sicklecell
The results of this study suggest that GPRC5D is an active target for immunotherapy in multiple myeloma. GPRC5D-targeted CAR T-cell therapy is a promising...
-
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial https://t.co/CdJd8E1VLA - view on twitter
Mashup Score:3
The Lancet Haematology2022 ASH annual meeting - 4 days
Mashup Score:3
Johannes Schetelig (University Hospital Technical University Dresden, Dresden, Germany) presented results from the phase 3 ASAP trial (NCT02461537), which tested whether intensive chemotherapy before...
-
ICYMI: Our Editors present their highlights from #ASH22. https://t.co/0HU7NTMhWO - view on twitter
More coverage:
#ash22
Our results suggest that a sex-informed approach can improve the personalised decision making process in patients with myelodysplastic syndromes and should be considered in...
-
ICYMI: A multicentre, observational cohort study suggests that a sex-informed approach can improve the personalised decision making process in patients with myelodysplastic syndromes. #mdssm #OpenAccess https://t.co/Kiq0SqXpcs https://t.co/Kiq0SqXpcs - view on twitter
Mashup Score:3
The Lancet HaematologyOn the basis of sex: outcomes in myelodysplastic syndromes - 4 days
Mashup Score:3
Sex has long been relevant in patients with myelodysplastic syndromes given there is a higher prevalence1 and poorer prognosis2 among men compared with women....
-
"These findings strongly support the integration of sex into the clinical risk assessment of myelodysplastic syndromes, albeit with only a modest hazard effect that appears specific to lower-risk disease phenotypes." Comment by @mjhochman and @AmyDeZern https://t.co/5WLstI9RlW - view on twitter
Mashup Score:9
The Lancet HaematologyUpfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial - 4 days
Mashup Score:9
KCd did not meet the criteria for non-inferiority compared with autologous HSCT, but the marginal difference in progression-free survival suggests that further studies are...
Mashup Score:2
The Lancet HaematologyUpfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial - 5 days
Mashup Score:2
KCd did not meet the criteria for non-inferiority compared with autologous HSCT, but the marginal difference in progression-free survival suggests that further studies are...
-
ICYMI: KCd did not meet the criteria for non-inferiority compared with autologous HSCT in patients w/ newly diagnosed multiple myeloma in the non-inferiority, CARDAMON trial. #mmsm #OpenAccess https://t.co/WU9Ucq1AMy https://t.co/WU9Ucq1AMy - view on twitter
Mashup Score:13
The Lancet HaematologyUpfront autologous transplantation still improving outcomes in patients with multiple myeloma - 5 days
Mashup Score:13
High-dose melphalan followed by autologous haematopoietic stem-cell transplantation (HSCT) has been the standard-of-care in multiple myeloma treatment for the past 30 years. However, with...
-
"The results... support the current role of upfront autologous HSCT in the treatment of multiple myeloma. However, they also highlight the need to evaluate a targeted selection of patients" Linked comment by @mbeksac56 and @HaydenpjPatrick. #mmsm https://t.co/ssCqnVbSG5 - view on twitter
More coverage:
#mmsm
New year, new beginning; out with the old, in with the new. Out with the tiny voice casting doubt onto every single achievement and...
NEW: Art of Medicine: @AnaKerep gives her thoughts on the ever present struggle of impostor syndrome. https://t.co/0DPxD5M85P - view on twitter